July 3, 2014 / 2:01 PM / 3 years ago

BRIEF-GSK and Genmab Get EU Approval for Arzerra

1 Min Read

July 3 (Reuters) - Gsk And Genmab Receive EU Authorisation For Arzerra (Ofatumumab) As First Line treatment for chronic lymphocytic leukaemia (cll) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based_therapy Source text for Eikon: Further company coverage: [GSK.L GEN.CO ]

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below